EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, Meijuan Huang, Toshiaki Takahashi, Xiaojing Lai, Koichi Goto, Kunlatida Maneenil, Ki Hyeong Lee, Manuel Cobo, Natalia Valdiviezo, Azura Evans und 4 weitere

European Journal of Cancer · 2026-06 · 240 · 116744

DOI: 10.1016/j.ejca.2026.116744 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Edurne Arriola und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hospital del Mar Research Institute, Department of Medical Oncology, Hospital del Mar, Passeig Marítim, Barcelona, Spain. Electronic address: earriol…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsPatient Reported Outcome MeasuresProtein Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodErbB ReceptorsIndolesMutationNeoplasm StagingProgression-Free SurvivalPyrimidinesQuality of Life

Stichwörter der Autor:innen

ChemoradiotherapyEGFR mutationNon–small cell lung cancerOsimertinibPatient-reported outcomesQuality of life

Substanzen

AcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • Hospital del Mar Research Institute, Department of Medical Oncology, Hospital del Mar, Passeig Marítim, Barcelona, Spain. Electronic address: earriola@psmar.cat.
  • Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina.
  • Department of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Türkiye.
  • Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Radiation Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Arriola, E., Casarini, I., Özgüroğlu, M., Huang, M., Takahashi, T., Lai, X., Goto, K., Maneenil, K., Lee, K. H., Cobo, M., Valdiviezo, N., Evans, A., Bolanos, A., Huang, X., Lai, R., & Ramalingam, S. S. (2026). Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. European Journal of Cancer, 240, 116744. https://doi.org/10.1016/j.ejca.2026.116744

Vancouver

Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, et al. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. European Journal of Cancer. 2026;240:116744. doi:10.1016/j.ejca.2026.116744

BibTeX
@article{Arriola2026,
  author = {Arriola, Edurne and Casarini, Ignacio and Özgüroğlu, Mustafa and Huang, Meijuan and Takahashi, Toshiaki and Lai, Xiaojing and Goto, Koichi and Maneenil, Kunlatida and Lee, Ki Hyeong and Cobo, Manuel and Valdiviezo, Natalia and Evans, Azura and Bolanos, Ana and Huang, Xiangning and Lai, Rachel and Ramalingam, Suresh S},
  title = {Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {240},
  pages = {116744},
  doi = {10.1016/j.ejca.2026.116744}
}
Kostenlos starten →